-
Mashup Score: 14Low dose azacitidine + venetoclax as maintenance therapy for patients with AML in remission - 3 day(s) ago
Here, we summarize a phase II study investigating the safety and efficacy of low-dose azacitidine + venetoclax as maintenance therapy in patients with acute myeloid leukemia in remission after either intensive or low-intensity induction.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
On April 30, 2024, the U.S. FDA granted Orphan Drug Designation to IGNK001, an investigational allogeneic NK cell therapy derived from healthy donors, for the treatment of patients with AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
Here, we summarize results from a pilot study by Wang et al. investigating the safety and tolerability of crenolanib plus intensive chemotherapy in adults with newly diagnosed FLT3-mutated acute myeloid leukemia.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 33Gemtuzumab ozogamicin plus 7 + 3 induction therapy in patients with intermediate-risk ND AML - 9 day(s) ago
Here, we summarize a real-world retrospective analysis by Awada et al. investigating whether the addition of gemtuzumab ozogamicin to intensive 7 + 3 induction therapy is beneficial in patients with intermediate-risk ND AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
During the 6th European CAR T-Cell Meeting, the AML Hub spoke to Sarah Tettamanti, Tettamanti Foundation Research Center, Monza, IT. We asked, What are the challenges associated with CAR T-cell therapy in patients with AML?
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4U.S. FDA grants Breakthrough Therapy Designation for ziftomenib - 11 day(s) ago
On April 22, 2024, the U.S. FDA granted Breakthrough Therapy Designation to ziftomenib, a novel therapy that targets the menin-KMT2A/MLL protein-protein interaction, for the treatment of NPM1-mutated R/R AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet-
🚨 NEWS 🚨 @US_FDA grants Breakthrough Therapy Designation for ziftomenib, a novel therapy that targets the menin-KMT2A/MLL protein-protein interaction, for the treatment of NPM1-mutated AML. Read more here 👉 https://t.co/B7yl3hgANv #AMLsm #leusm #leukemia #MedicalEducation https://t.co/uIlePVyzDZ
-
-
Mashup Score: 5
Here, we summarize a validation of the Oncomine Myeloid Assay GX v2 in myeloid malignancies published by Zbieranski and Insuasti-Beltran.1 in The Journal of Molecular Diagnostics.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Annamycin granted Orphan Drug Designation by the EMA - 12 day(s) ago
On April 18, 2024, the European Medicines Agency granted Orphan Drug Designation to annamycin, a next-generation anthracycline, for the treatment of patients with AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1BVX001 granted Orphan Drug Designation by the U.S. FDA - 15 day(s) ago
On April 17, 2024, the U.S. Food and Drug Administration granted Orphan Drug Designation to BVX001, a novel twin CD33/CD7 targeting bispecific antibody-drug conjugate, for the treatment of patients with acute myeloid leukemia.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Annamycin granted Orphan Drug Designation by the EMA - 15 day(s) ago
On April 18, 2024, the European Medicines Agency granted Orphan Drug Designation to annamycin, a next-generation anthracycline, for the treatment of patients with AML.
Source: aml-hub.comCategories: General Medicine News, Onc News and JournalsTweet
Can low-dose azacitidine + venetoclax be used as maintenance therapy in patients with AML in remission after either intensive or low-intensity induction? Check out our summary of a recent phase II trial here: https://t.co/jdFY5sv8ih #AMLsm #leusm #leukemia #MedicalEducation https://t.co/yYaUsMSj71